The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | An analysis of TP53 mutation in AML and HR-MDS
Jan Philipp Bewersdorf, MD, Yale University, New Haven, CT, gives a detailed overview on TP53 mutations in patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (HR-MDS). First, Dr Bewersdorf briefly explains the poorer patient outcomes associated with TP53 mutations, including shorter duration of remission and lower response rates. Following this, Dr Bewersdorf focuses on the findings from a recent post-hoc analysis, which used data from the Phase II FUSION trial (NCT02775903) to evaluate the effects of TP53 mutation vs wild type in patients with AML and MDS. Dr Bewersdorf explains the results from this analysis, including the effect of this mutation on overall survival (OS), response rate, and gene expression pattern. To conclude, Dr Bewersdorf discusses how different types of TP53 mutations are being increasingly analyzed, and that further exploration of this mutation is important for the future of research in this area. This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, 2021.
